Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Novartis AG stock logo
NVS
Novartis
$140.97
-0.1%		$150.66
$121.57
▼
$170.46
$269.14B0.412.37 million shs2.14 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Novartis AG stock logo
NVS
Novartis
+0.01%-3.11%-13.21%-11.80%+7.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Novartis AG stock logo
NVS
Novartis
$140.97
-0.1%		$150.66
$121.57
▼
$170.46
$269.14B0.412.37 million shs2.14 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Novartis AG stock logo
NVS
Novartis
+0.01%-3.11%-13.21%-11.80%+7.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Novartis AG stock logo
NVS
Novartis
2.20
Hold$148.405.27% Upside

Current Analyst Ratings Breakdown

Latest NVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Novartis AG stock logo
NVS
Novartis
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell
9/17/2026
Novartis AG stock logo
NVS
Novartis
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/17/2026
Novartis AG stock logo
NVS
Novartis
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/11/2026
Novartis AG stock logo
NVS
Novartis
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetHold$147.00 ➝ $130.00
9/10/2026
Novartis AG stock logo
NVS
Novartis
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeReduce ➝ Hold$123.00 ➝ $136.00
9/10/2026
Novartis AG stock logo
NVS
Novartis
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeReduce ➝ Hold$123.00 ➝ $136.00
9/8/2026
Novartis AG stock logo
NVS
Novartis
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
9/8/2026
Novartis AG stock logo
NVS
Novartis
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSector Perform
9/8/2026
Novartis AG stock logo
NVS
Novartis
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/9/2026
Novartis AG stock logo
NVS
Novartis
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Novartis AG stock logo
NVS
Novartis
$56.69B4.74$10.74 per share13.13$22.04 per share6.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Novartis AG stock logo
NVS
Novartis
$13.98B$6.6321.2614.362.7323.29%38.56%14.47%10/27/2026 (Estimated)

Latest NVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/27/2026Q3 2026
Novartis AG stock logo
NVS
Novartis
$2.24N/AN/AN/A$14.59 billionN/A
7/21/2026Q2 2026
Novartis AG stock logo
NVS
Novartis
$2.17$2.41+$0.24$1.71$14.07 billion$14.41 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Novartis AG stock logo
NVS
Novartis
$3.082.18%+5.28%46.46%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Novartis AG stock logo
NVS
Novartis
0.89
0.86
0.67

Institutional Ownership

CompanyInstitutional Ownership
Novartis AG stock logo
NVS
Novartis
13.12%

Insider Ownership

CompanyInsider Ownership
Novartis AG stock logo
NVS
Novartis
0.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Novartis AG stock logo
NVS
Novartis
75,2671.91 billion1.91 billionOptionable

Recent News About These Companies

Novartis Signs Deal With Abogen For MRNA Therapies
October 2 at 6:04 PM  |  rttnews.comhttps://www.rttnews.com/3696234/novartis-signs-deal-with-abogen-for-mrna-therapies.aspx
Novartis Signs RNA Therapy Licensing Deal With China’s Abogen Worth Up to $7.8 Billion
October 2 at 8:02 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novartis-signs-rna-therapy-licensing-102433389.html
Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
October 2 at 7:18 AM  |  cnbc.comhttps://www.cnbc.com/2026/10/02/novartis-abogen-china-biotech-deal.html
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal
October 2 at 6:48 AM  |  wsj.comhttps://www.wsj.com/health/pharma/novartis-to-license-drug-from-chinas-abogen-in-up-to-7-8-billion-deal-4ad8509c
Novartis signs mRNA deal for about $7.8 billion with China's Abogen
October 2 at 3:31 AM  |  reuters.comhttps://www.reuters.com/legal/litigation/novartis-strikes-about-78-billion-mrna-deal-with-chinas-abogen-2026-10-02/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
October 1 at 10:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-novartis-ag---nvs-302895440.html
Novartis Falls as Investors Continue to Digest September Trial Setbacks
September 30 at 5:30 PM  |  quiverquant.comQ
Novartis AG (NVS) Shares Fall 0.8% -- What GF Score of 78 Tells Investors
September 29, 2026  |  gurufocus.comhttps://www.gurufocus.com/news/9102503/novartis-ag-nvs-shares-fall-08-what-gf-score-of-78-tells-investors
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3371428/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-novartis-ag-nvs.html
Zacks Research Weighs in on Novartis' Q1 Earnings (NYSE:NVS)
September 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31063732
Zacks Research Issues Negative Outlook for Novartis Earnings
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-zacks-research-issues-negative-outlook-for-novartis-earnings-2026-09-29/
Novartis (NYSE:NVS) Stock Sold by Rep. Kevin Hern
September 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/congress-novartis-nyse-nvs-stock-sold-by-rep-kevin-hern-2026-09-29/
Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure?
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novartis-nvs-more-growth-ahead-232106682.html
Zacks Research Brokers Boost Earnings Estimates for Novartis
September 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31056374
Novartis Stock Earnings Estimates Raised by Zacks Research
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-novartis-stock-earnings-estimates-raised-by-zacks-research-2026-09-28/
Novartis AG $NVS Shares Sold by State Street Corp
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-novartis-ag-nvs-shares-sold-by-state-street-corp-2026-09-26/
A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/top-novartis-nvs-shareholder-says-232101327.html
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
September 25, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/novartis-nvs-and-bristol-myers-bmy-pause-autoimmune-car-t-studies-can-their-programs-recover-1840433/
FY2027 EPS Estimates for Novartis Lifted by Erste Group Bank
September 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31046838
Envestnet Asset Management Inc. Acquires 19,595 Shares of Novartis AG $NVS
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-envestnet-asset-management-inc-acquires-19595-shares-of-novartis-ag-nvs-2026-09-24/
QRG Capital Management Inc. Raises Stock Position in Novartis AG $NVS
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-qrg-capital-management-inc-raises-stock-position-in-novartis-ag-nvs-2026-09-23/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Amgen logo displayed on a glass panel in a laboratory setting with microscopes and sample vials.
Amgen Drops 10% on a Trial It Didn't Even Run
By Chris Markoch | September 11, 2026
Novartis stock logo

Novartis NYSE:NVS

$140.97 -0.08 (-0.06%)
Closing price 10/2/2026 03:59 PM Eastern
Extended Trading
$140.73 -0.24 (-0.17%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas